Amgen's Bkemv Approved As First Interchangeable Biosimilar To Soliris

(RTTNews) - The U.S. Food and Drug Administration has approved Amgen Inc.'s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab), developed by British drug major AstraZeneca's Rare Disease unit Alexion Pharmaceuticals, to treat two rare diseases https://www.nasdaq.com/articles/amgens-bkemv-approved-first-interchangeable-biosimilar-soliris